We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

55 hedge funds and large institutions have $212M invested in Arbutus Biopharma in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $864K

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less funds holding

Funds holding: 63 → 55 (-8)

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

52% less capital invested

Capital invested by funds: $442M → $212M (-$230M)

Holders
55
Holders Change
-8
Holders Change %
-12.7%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
17
Reduced
14
Closed
18
Calls
$1.4M
Puts
$864K
Net Calls
+$537K
Net Calls Change
-$571K

Top Buyers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
+$6.72M
2
HM
HealthCor Management
New York
+$3.77M
3
SM
Sabby Management
Florida
+$3.72M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.52M
5
Axa
Axa
France
+$3.33M

Top Sellers

Rank Fund Capital Flow
1
BRC
Blue Ridge Capital
New York
-$20.2M
2
RIM
RS Investment Management
California
-$11.5M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$9.2M
4
Invesco
Invesco
Georgia
-$5.1M
5
AC
Ascend Capital
California
-$4.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
26
Telemetry Investments
New York
$380K +$52K +5,860 +10%
TI
27
Trexquant Investment
Connecticut
$313K +$457K +51,500 New
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$253K +$12.1K +1,368 +3%
Mackenzie Financial
29
Mackenzie Financial
Ontario, Canada
$243K – – –
KPF
30
K2 Principal Fund
Ontario, Canada
$226K -$48.8K -5,500 -13%
State Street
31
State Street
Massachusetts
$208K +$304K +34,258 New
Bank of America
32
Bank of America
North Carolina
$201K +$52.3K +5,895 +22%
VAM
33
Visium Asset Management
New York
$193K +$281K +31,700 New
Ameriprise
34
Ameriprise
Minnesota
$174K -$355K -40,030 -58%
SLG
35
Stanley-Laman Group
Pennsylvania
$157K – – –
Jane Street
36
Jane Street
New York
$155K +$225K +25,374 New
AFM
37
Anson Funds Management
Texas
$152K – – –
ARTA
38
A.R.T. Advisors
New York
$137K +$201K +22,617 New
Geode Capital Management
39
Geode Capital Management
Massachusetts
$122K +$25.4K +2,866 +17%
AL
40
Airain Ltd
Guernsey
$117K +$170K +19,135 New
Citigroup
41
Citigroup
New York
$103K -$223K -25,150 -60%
Fidelity Investments
42
Fidelity Investments
Massachusetts
$71K +$103K +11,600 New
NYLIM
43
New York Life Investment Management
New York
$60K -$91.8K -10,357 -51%
UBS Group
44
UBS Group
Switzerland
$46K -$61.6K -6,949 -48%
Simplex Trading
45
Simplex Trading
Illinois
$32K -$66.1K -7,451 -58%
TRCT
46
Tower Research Capital (TRC)
New York
$32K – – –
GXMC
47
Global X Management Company
New York
$31K +$45.5K +5,134 New
Wells Fargo
48
Wells Fargo
California
$17K -$2.31K -260 -8%
Creative Planning
49
Creative Planning
Kansas
$9K -$97.5K -11,000 -88%
WIC
50
Woodmont Investment Counsel
Tennessee
$5K +$7.09K +800 New
1
2
3

ABUS Hedge Fund Activity: Q3 2015 in Review

55 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2015, worth a combined $212M — down 52% from $442M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ABUS and 11 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 17 added.

The largest buyer was Primecap Management, adding an estimated $6.72M. The largest seller was Blue Ridge Capital, exiting entirely with an estimated $20.2M sold.

  • 55 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2015, down from 63 in Q2 2015.
  • Funds reported $212M of Arbutus Biopharma stock for Q3 2015, down 52% quarter-over-quarter.
  • 11 funds opened new Arbutus Biopharma positions in Q3 2015 and 18 closed out, a net change of -7 holders.
  • The largest Arbutus Biopharma buyer in Q3 2015 was Primecap Management, an estimated $6.72M added.
  • The largest Arbutus Biopharma seller in Q3 2015 was Blue Ridge Capital, an estimated $20.2M sold.

Based on aggregated 13F filings for Q3 2015.